Fennec Pharmaceuticals crossed a threshold this quarter that the market spent three years waiting to see: a commercial-stage specialty pharmaceutical company now generating operating income on a generally accepted accounting principles basis while its sole product, PEDMARK, compounds into the adolescent and young adult population. The inflection is not an accounting artifact. A patent settlement with Cipla in March removed the nearest generic threat and reset the exclusivity horizon into the next decade, and the sales force expansion that depressed results a year ago now registers as volume growth rather than cost.
Revenue of roughly eighteen million dollars in the second quarter, up from just under ten million a year earlier, combined with a swing from an operating loss to a positive operating profit, marks the first sustained stretch in which the company has earned through its fixed cost base. Selling and marketing spend nearly doubled as the field force scaled toward full national coverage, yet gross margin on product sales sits near ninety percent, so incremental volume drops through to the bottom line at a high conversion rate.
The question the next several quarters resolve is whether the adolescent and young adult expansion, now the principal growth driver, sustains its pace or plateaus once the earliest adopter centers are saturated. The falsifiable data point is the trajectory of sequential product revenue across the back half of the year against a commercial organization still hiring toward full coverage.